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Introduction  and  aim: It has  been  proposed  that  plasma  concentration  of bilirubin,  an  endogenous  antiox-
idant,  is  protective  against  diseases  mediated  by  increased  oxidative  stress,  including  cardiovascular
diseases  (CVD)  and  cancer.  To  examine  this  hypothesis,  we  investigated  the  relationship  between  plasma
bilirubin  concentrations  and  bilirubin  UDP-glucuronosyl  transferase  (UGT1A1)  promoter  gene variations
(associated  with  increased  bilirubin  concentrations)  with  total/CVD  and cancer  mortality.
Materials  and  methods:  A nested  case–control  study  was  conducted  within  the  Polish  arm  of  the  HAPIEE
cohort.  At  baseline  in  2002–2005,  participants  were examined  in  detail.  Mortality  follow-up  (median
(IQR)  between  blood  draw  and  death  was  3.7  (2.1–5.1)  years)  was  performed  by linkage  with  regional
and  national  death  registers.  Plasma  biomarkers  were  analysed  in  all subjects  who  died from  any  cause
(cases,  n =  447)  and  in  a random  subsample  of survivors  (controls,  n =  1423).
Results:  There  was  a strong  negative  association  between  plasma  bilirubin  levels and  total  and  cancer
mortality,  expressed  more  profoundly  in  men.  The  adjusted  OR of  deaths  from  all  causes  and  cancer,
comparing  the  highest  vs. lowest  plasma  bilirubin  categories  were  0.61  (95%  CI: 0.42–0.87)  and  0.39
(0.24–0.65),  respectively.  There  was  no  association  of  bilirubin  with  CVD  mortality.  The  UGT1A1*28
allele,  a  genetic  marker  of  raised  bilirubin,  was  also  negatively  associated  with  total/cancer  mortality,
although  the  associations  were not  statistically  signiﬁcant.
Discussion:  Both  the observational  and  genetic  associations  support  the  negative  relationship  between
bilirubin  and  total  mortality;  this  association  appears  to be  driven  by cancer  mortality,  while  that  with
CVD  mortality  is  not  evident.
©  2019  Fundacio´n  Clı´nica  Me´dica  Sur, A.C. Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open  access
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The role of increased oxidative stress in the pathogenesis of
ardiovascular disease (CVD) and cancer, and the associated effects
f various antioxidants, have been intensively discussed in the
iterature [1,2]. In this context, bilirubin, the ﬁnal product of the
eme catabolic pathway in the intravascular compartment, is
ecognised as one of the most potent endogenous antioxidants.
levated systemic concentrations of bilirubin were for decades
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considered an ominous sign of liver diseases, but recent data
suggest that mildly increased bilirubin concentrations might exert
potent protective effects against oxidative stress-related diseases,
including cardiovascular and cancer diseases [3–5], and this may
result in lower risk of total mortality [3]. This protective rela-
tionship appears to be linear; it has been reported that each unit
increase of systemic bilirubin concentrations has been associated
with decrease in cardiovascular and cancer risk [6,7] while plasma
bilirubin concentrations below 10 mol/L, although still within
the current physiological range, appear to confer increased risks
of a variety of oxidative stress-mediated diseases [8].
Bilirubin is metabolised in the liver tissue by the conjugation
enzyme UGT1A1 (bilirubin UDP-glucuronosyl transferase 1),
whose gene (OMIM accession no. 191740) is the major genetic
, S.L.U. This is an open access article under the CC BY-NC-ND license (http://
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eterminant of its systemic bilirubin concentrations [9]. In fact,
nherited mild deﬁciency of UGT1A1 is the basis of a Gilbert
yndrome (OMIM accession no. 143500), also known as benign
yperbilirubinemia. In most of Caucasian subjects, Gilbert syn-
rome is caused by the functional (TA) repeat variation located
ithin the ATATAA element in the promoter UGT1A1 gene region.
n comparison with the shorter wild-type (TA)6 allele, the presence
f the longer allele (TA)7 (known also as UGT1A1*28 allele) is asso-
iated with lower gene expression and bilirubin concentrations
n (TA)7 homozygotes are signiﬁcantly higher than in carriers
f at least one (TA)6 allele [10]. It is important to stress, that
he penetrance of Gilbert syndrome genotype is only 50% (vir-
ually only ½ of these subjects manifest with mild unconjugated
yperbilirubinemia) [10], a phenomenon confounding results of
tudies evaluating the effect of UGT1A1 gene mutations on various
henotypes.
The aim of our study was thus to analyse the prospective asso-
iations between the plasma concentrations of bilirubin, the TA
GT1A1 promoter gene tandem repeat polymorphism, and total,
ardiovascular and cancer mortality in a nested case–control study
stablished within a large population-based cohort study in Poland.
. Material and methods
.1. Subjects in the cohort and in the nested case–control study
This study used data collected by the Polish arm of the multi-
entre HAPIEE (Health, Alcohol, and Psychosocial factors in Eastern
urope) cohort study [11,12]. At baseline in 2002–2005, the study
xamined a random sample of men  and women aged 45–69 years
iving in 4 districts of the city of Krakow, Poland. A total of 10,728
ndividuals were recruited (response rate 61%), 8860 of whom pro-
ided a blood sample. All examined subjects were of self-reported
aucasian ethnicity. The study complied with the Helsinki Decla-
ation and was approved by the Ethics Committees of University
ollege London and the Jagiellonian University, Krakow. All sub-
ects provided a written informed consent.
Since there was not sufﬁcient funding for laboratory analyses
f all blood samples, this report is based on a nested case–control
tudy established within this cohort. The nested case–control has
een described in detail elsewhere (including 3 other cohorts with-
ut bilirubin measurements cohort) [13]. Brieﬂy, cases were all
ubjects who died from any cause during the follow-up (cases,
 = 447), and controls were a random subsample of survivors (con-
rols, n = 1423). Controls were chosen from participants who  were
live at the time when the analytical sample was selected. The date
f this was the 31st December 2010, which was, on average, 7 years
fter baseline data collection.
.2. Measurements and mortality follow-up
Participants completed a face-to-face interview, covering their
edical history, healthy behaviours and socio-demographic and
sychosocial characteristics, underwent an examination and pro-
ided a venous blood sample. Local and national death registers in
rakow were used to identify mortality rates amongst the partic-
pants. Causes of death were determined using the 10th revision
f the International Classiﬁcation of Diseases (ICD): CVD (I00-
99), cancer (C00-D48) or causes other than those above (all other
CD codes). Follow-up time for each participant was  calculated
s the time between enrolment to the study and date of either
eath or the last contact (for those who did not die); the mean
ollow-up of subjects in the nested case–control study was  6.4
ears. The median (IQR) follow-up time of cases was  3.7 years
2.1–5.1).logy 18 (2019) 379–385
1.3. Laboratory analyses
Bilirubin, ALT, urea and CRP in frozen baseline plasma sam-
ples were determined on automatic analyser (UniCel DxC 800
Synchron Clinical Systems, Beckman Coulter, UK) using com-
mercially available kits and reference materials from Beckman
Coulter at Wageningen University (The Netherlands). DNA has
been isolated by a modiﬁed salting-out method [14]. TA repeat
polymorphism within the UGT1A1 gene has been genotyped by
the KASPTM technology custom assay (www.lgcgroup.com). This
method is unable to detect rare alleles obtaining the 5 and 8
repeats, but as these subjects represent less than 1% of the gen-
eral population (https://www.ncbi.nlm.nih.gov/projects/SNP/snp
ref.cgi?rs=8175347), they were neglected in the further analyses.
1.4. Statistical analyses
The associations of plasma bilirubin concentrations with mor-
tality outcomes were analysed by multivariable adjusted logistic
regression in several steps. We categorised plasma bilirubin con-
centrations using 17 and 10 mol/L cut-offs in order to make the
results more meaningful for clinical practice and comparable with
previous studies (the value of 17 mol/L is the upper limit of the
normal bilirubin concentration, while levels lower than 10 mol/L
have been proposed by previous studies as a potential risk factor
for cardiovascular mortality [15]).
In model 1, the relationships were adjusted for participants’ age
and sex (the basic confounders which are adjusted for in most
epidemiological studies). In model 2, the odds ratios were fur-
ther adjusted for education, marital status, alcohol intake, smoking,
body mass index, energy intake and the ratio of total/HDL choles-
terol (usually found to be related to the exposure (plasma bilirubin)
or the outcome (mortality) in most studies and therefore consid-
ered as potential confounders). In model 3, odds ratios were further
adjusted for plasma ALT, GGT, CRP and urea as potential biomarkers
(which have also been shown to be related to bilirubin and mortal-
ity, in order to assess the strength of the associations independently
of these factors). The analyses of mortality by the UGT1A1 genotype
were adjusted for age and sex (model 1, as above) and additionally
for bilirubin concentrations to assess whether the effect of geno-
type on mortality was explained by bilirubin, or whether there is
another pathway linking the genotype with the outcome (model
2). This part of the analysis was  a Mendelian randomisation study
where a genetic marker of a speciﬁc phenotype (e.g. plasma biliru-
bin) is used to test a potential causal association between the
phenotype and disease. The Mendelian randomisation method is
often seen as a close parallel to randomised controlled trial and,
if the assumptions are fulﬁlled, it should provide unbiased and
unfounded estimates between the two variables [16,17].
The interaction between sex and bilirubin concentrations, as
well as between sex and UGT1A1 genotype, were tested in the asso-
ciation with mortality by the likelihood ratio test which compared
the nested models with or without multiplicative interaction term.
There were no statistically signiﬁcant interactions with sex in any
of the examined associations. Therefore, men and women  were
analysed together.
All statistical analyses were carried out using the 13.1 version
of the statistical software STATA (StataCorp, Texas, USA), p-values
<0.05 were considered statistically signiﬁcant.
2. ResultsThe nested case–control study consisted from 1870 individuals,
of whom 447 were cases (i.e. they died from any cause, of which 139
were from CVD and 211 from cancer); the 1423 survivors served
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Table  1
Descriptive characteristics of the study sample.
Cases
(all deaths)
Controls p-value*
Number of subjects 447 1423
Age  (years), mean (SD) 61.6 (6.5) 60.8 (6.7) 0.048
Males,  n (%) 305 (68.2) 971 (68.2) 0.999
Current  smoking, n (%) 194 (43.4) 383 (26.9) <0.001
BMI  (kg/m2), mean
(SD)
28.0 (5.1) 28.3 (4.3) 0.388
Total  cholesterol
(mmol/L), mean (SD)
5.7 (1.2) 5.8 (1.0) 0.173
Triacylglycerols
(mmol/L)
median (IQR)
1.5
(1.1–2.1)
1.5
(1.1–2.0)
0.998
Bilirubin (mol/L)
median (IQR)
12.0
(9.8–15.2)
12.9
(10.9–16.1)
<0.001
ALT (IU/L)
median (IQR)
20.1
(15.4–27.0)
21.1
(16.8–27.4)
0.022
GGT (IU/L)
median (IQR)
21.3
(8.4–40.3)
15.7
(6.8–31.1)
<0.001
CRP (mg/L)
median (IQR)
2.5
(1.1–5.6)
1.7
(0.9–3.3)
<0.001
Urea (mmol/L)
median (IQR)
4.6
(3.7–5.8)
4.8
(4.0–5.8)
0.021
SD = standard deviation, IQR = interquartile range.
* Calculated with chi-square test, t-test or Spearman’s rank correlation, depending on the nature of the variable.
Values in bold represent signiﬁcant differences.
Table 2
Distribution of UGT1A1 genotypes in the study sample (cases and controls combined) and values of bilirubin, ALT, GGT, CRP and urea by UGT1A1 genotype.
UGT1A1 genotype p-value*
6/6 6/7 7/7
Number of subjects (%) 759 (40.6) 844 (45.1) 267 (14.3)
Bilirubin (mol/L), median (IQR) 11.7 (10.0–13.9) 13.0 (10.9–15.6) 19.1 (14.6–25.0) <0.001
ALT  (IU/L), median (IQR) 21.0 (16.7–27.0) 20.9 (16.5–27.9) 20.8 (16.2–26.9) 0.519
GGT  (IU/L), median (IQR) 17.4 (7.1–34.1) 16.7 (7.0–33.7) 16.8 (7.0–30.3) 0.311
CRP  (mg/L), median (IQR) 1.8 (0.9–3.6) 1.9 (0.9–3.9) 1.8 (0.9–3.8) 0.596
Urea  (mmol/L), median (IQR) 4.9 (4.0–5.8) 4.7 (3.9–5.7) 4.8 (3.8–5.8) 0.105
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p* p-value for trend estimated by Spearman’s rank correlation test. IQR, interquart
ata expressed as medians and IQR. Values in bold represent signiﬁcant differences
s controls. Descriptive characteristics of subjects included in the
ested case–control study are shown in Table 1. The median plasma
ilirubin concentration in the overall sample was  12.8 mol/L
13.5 mol/L in men, 11.6 mol/L in women). Compared to controls
ubjects who died had signiﬁcantly lower plasma bilirubin concen-
rations (Table 1). Clinically important elevations of ALT and GGT
ctivities were seen in 8.6% and 19.5% of subjects, respectively.
The distribution of UGT1A1 genotypes was in agreement with
W equilibrium (p = 0.19), and the allele frequencies were similar
o the other Caucasian populations (Table 2) [10]. As expected, there
as an association between the UGT1A1 genotypes and plasma
ilirubin concentrations; 7/7 homozygotes had signiﬁcantly higher
lasma bilirubin concentrations compared to carriers of at least
ne allele 6 (Table 2). Other biochemical and anthropometrical
arameters of interest (ALT, GGT, CRP, urea) were distributed inde-
endently of the UGT1A1 repeat polymorphism.
After controlling for age and sex, there was  a strong negative
ssociation of plasma bilirubin categories with risk of death from
ll causes and cancer mortality but not from CVD (Table 3). These
esults remained signiﬁcant even after adjusting for potential con-
ounders, including age, education, marital status, alcohol intake,
moking, BMI, energy intake, total/HDL cholesterol ratio (model 2).
n the adjusted model, the odds ratios in the highest vs. lowest
ilirubin categories for death from all causes, cancer and CVD were
.61 (95% CI: 0.42–0.87), 0.39 (0.24–0.65) and 1.03 (0.58–1.83),
espectively (Table 3). After additionally adjusting for elevated
lasma ALT, GGT activities, as well as CRP and urea concentrationsge.
(model 3), the pattern of results remained similar, although the con-
ﬁdence intervals became wider due to loss of statistical power in
the multivariable model. All the studies on the association between
bilirubin and clinical outcomes published so far have paid extreme
attention to gender with female sex having negligible relationship,
whereas males almost always having beneﬁts from higher bilirubin
concentrations. For this reason we also conducted gender-speciﬁc
analyses. In these additional analyses, investigated associations
were stronger in men  than women (Table 4), although the inter-
actions between bilirubin and sex were not statistically signiﬁcant.
The associations of the UGT1A1*28 allele (a genetic marker
of systemic bilirubin concentrations) with mortality risks showed
similar patterns as plasma bilirubin concentrations, although the
associations did not reach statistical signiﬁcance (Table 5). Impor-
tantly, the adjustment for plasma bilirubin almost attenuated the
(non-signiﬁcant) associations of the polymorphism with all-cause
and cancer mortality; indicating that the effect of genotype was, as
hypothesised, driven predominantly by plasma bilirubin concen-
trations.
3. Discussion
This case–control study, nested in a population-based cohort
in a Krakow urban population sample, found strong negative
associations of plasma bilirubin with all-cause mortality driven
predominantly by the effect on cancer but not CVD mortality.
These observational associations were supported by the Mendelian
382 L. Vitek et al. / Annals of Hepatology 18 (2019) 379–385
Table  3
Odds ratios (OR) and 95% conﬁdence intervals (95% CI) of mortality by plasma bilirubin concentrations calculated with logistic regression models.
Cause of death Plasma bilirubin (mol/L) Deaths
(n)
Model 1 Model 2 Model 3
OR (95% CI) OR (95% CI) OR (95% CI)
All causes
(n = 447)
<10 120 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17  253 0.49 (0.37–0.64) 0.60 (0.45–0.79) 0.62 (0.47–0.82)
≥17  74 0.47 (0.33–0.66) 0.61 (0.42–0.87) 0.63 (0.43–0.92)
p-value for trend <0.001 0.004 0.010
Sex  interaction p-value 0.659 0.746 0.795
CVD
(n  = 139)
<10 30 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17  82 0.73 (0.47–1.13) 0.87 (0.55–1.37) 0.91 (0.58–1.44)
≥17  27 0.79 (0.45–1.38) 1.03 (0.58–1.83) 1.09 (0.61–1.95)
p-value for trend 0.407 0.923 0.793
Sex  interaction p-value 0.240 0.190 0.187
Cancer
(n  = 211)
<10 68 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17  117 0.44 (0.32–0.61) 0.52 (0.36–0.72) 0.54 (0.38–0.76)
≥17  26 0.32 (0.20–0.52) 0.39 (0.24–0.65) 0.41 (0.25–0.69)
p-value for trend <0.001 <0.001 <0.001
Sex  interaction p-value 0.549 0.638 0.706
Other  causes
(n = 97)
<10 22 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17  54 0.69 (0.41–1.16) 0.86 (0.51–1.48) 0.87 (0.50–1.50)
≥17  21 0.85 (0.45–1.60) 1.08 (0.56–2.09) 1.00 (0.51–1.98)
p-value for trend 0.628 0.820 0.999
Sex  interaction p-value 0.251 0.183 0.158
Model 1: Adjusted for age and sex.
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todel 2: Additionally adjusted for education, marital status, alcohol intake, smokin
odel 3: Adjusted for all variables in model 2 and plasma ALT and GGT activities, a
alues in bold and italics are highlighting stadistical signiﬁcance of the results.
andomisation analyses; although non-signiﬁcant, the patterns of
ssociations of mortality with a genetic marker of raised biliru-
in were similar to results of analyses using plasma bilirubin. In
heory, with data available on bilirubin, genotypes and mortality
utcomes in the same dataset, it would be possible to formally con-
uct a one sample Mendelian randomisation using a two-stage least
quares regression analysis. However, a larger sample size and/or
igher number of deaths would be necessary to achieve sufﬁcient
tatistical power.
There is growing evidence from experimental and clinical stud-
es [3,4] that mildly elevated systemic bilirubin concentrations
ave potent anti-atherogenic [5], anti-proliferative [7,18], and anti-
geing [19] effects. This association, however, seems to be valid only
hen the elevated bilirubin is not a consequence of an underlying
iver disease [6]. Indeed, elevated liver enzyme activities predict
ardiovascular events [20,21], thus underlying liver disease clearly
liminates the potential beneﬁcial effects of bilirubin. It is impor-
ant to note, that the prevalence of elevated liver enzymes in the
eneral population is as high as 10–20% [22], which is exactly what
e found in our current study.
The beneﬁcial effects of bilirubin on mortality have been shown
n several epidemiological studies. The ﬁrst study, in 2001, a 10-
ear follow-up retrospective investigation of more than 11,000
elgian men  and women [23], reported a signiﬁcant negative asso-
iation of bilirubin with all-cause and cancer mortality in men  but
ot in women; surprisingly, no association was found with CVD
ortality. Another large study by Fulks et al., included almost 2 mil-
ion insurance applicants, found an negative association between
ll-cause mortality and bilirubin levels [24]. Serum bilirubin levels
ad a strong and independent protective impact on the associa-
ion with all-cause and CVD mortality in a study by Ajja et al. in
 male population [25]. In a prospective study by Horsfall et al.
26] in a statin-treated population of approximately 130,000 par-
icipants, a negative relationship between bilirubin concentrations
nd all-cause mortality risk was observed, whereas the relation-
hip between bilirubin and CVD/myocardial infarction events was
-shaped [26]. In a second report, the same group analysed mor-
ality rates in participants diagnosed with Gilbert syndrome; theseI, energy intake, total cholesterol/HDL ratio.
P and urea concentration.
subjects had half the mortality rate compared to controls [27].
Protective effects of bilirubin on overall mortality were reported
also from a prospective study on haemodialysed patients by Chen
et al. [28]. Importantly, subjects with Gilbert syndrome genotype
(UGT1A1*28 homozygosity) had one fourth the risk for all-cause
mortality as compared to the wild-type allele carriers. A signiﬁ-
cant negative correlation between serum bilirubin and all-cause
mortality was observed also in NHANES study on elderly popula-
tion [29], although no detailed analysis was provided. Consistently,
serum bilirubin concentrations below 10.5 mol/L were found to
be a risk factor for cardiovascular mortality in a small Serbian older
population [30].
On the other hand, no survival advantage of higher serum
bilirubin concentrations was  observed among older persons by
Boland et al. [31] and, higher baseline bilirubin levels predicted
slightly increased mortality in the Ludwigshafen Risk and Cardio-
vascular Health study (although confusingly, a UGT1A1*28 gene
variant predicted lower overall mortality [32]. No signiﬁcant asso-
ciations between serum bilirubin and either all-cause, CVD or
non-CVD mortality were observed in Diabetes Heart Study [33].
Similarly, bilirubin was  not associated with cancer mortality in the
EPIC-Heidelberg cohort [34]. Overall, although not completely con-
sistent, most available studies suggest a beneﬁcial effect of bilirubin
on all-cause mortality, driven predominantly by the effect on can-
cer, but in some studies also on CVD.
Our results conﬁrm data from previous studies since they are
consistent with the majority of published reports. In our study,
the association with all-cause mortality was  driven mainly by can-
cer mortality, while that with cardiovascular mortality was  not
observed. One of the reasons for this observation may  lie in the
relatively young age of the examined population (61.6 ± 6.5 years),
in which cancer was found a leading mortality cause.
The association between UGT1A1 promoter gene variations
and mortality rates was  not signiﬁcant (most likely due to low
penetrance of UGT1A1*28 mutation [10]) but the direction of
the association also suggests protective effects. The observation
that the adjustment for bilirubin virtually eliminated the (non-
signiﬁcant) effect of the genotype is important because it conﬁrms
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Table  4
Odds ratios (OR) and 95% conﬁdence intervals (95% CI) of mortality by plasma bilirubin concentrations by sex, calculated with logistic regression.
(a) men
Causes of death Plasma bilirubin (mol/L) Deaths(n) Model 1 Model 2 Model 3
OR (95% CI) OR (95% CI) OR (95% CI)
All cause
(n = 305)
<10 71 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17  173 0.44 (0.31–0.62) 0.55 (0.39–0.80) 0.57 (0.40–0.83)
≥17 61 0.42 (0.28–0.63) 0.58 (0.38–0.90) 0.59 (0.38–0.92)
p-value for trend <0.001 0.024 0.031
CVD
(n  = 98)
<10 21 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17  55 0.55 (0.33–0.95) 0.65 (0.37–1.14) 0.72 (0.41–1.26)
≥17  22 0.61 (0.33–1.16) 0.81 (0.41–1.56) 0.92 (0.46–1.79)
p-value for trend 0.184 0.606 0.868
Cancer
(n  = 134)
<10 39 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17 75 0.37 (0.23–0.57) 0.44 (0.28–0.70) 0.45 (0.28–0.71)
≥17  20 0.26 (0.15–0.47) 0.35 (0.19–0.64) 0.35 (0.19–0.64)
p-value for trend <0.001 <0.001 0.001
Other cause
(n = 73)
<10 11 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17 43 0.97 (0.49–1.92) 1.27 (0.62–2.60) 1.24 (0.60–2.58)
≥17  19 1.16 (0.54–2.50) 1.51 (0.67–3.40) 1.31 (0.56–3.03)
p-value for trend 0.641 0.316 0.560
(b)  Women
Causes of death Plasma bilirubin (mol/L) Deaths(n) Model 1 Model 2 Model 3
OR (95% CI) OR (95% CI) OR (95% CI)
All cause
(n = 142)
<10 49 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17  80 0.57 (0.37–0.87) 0.66 (0.43–1.03) 0.71 (0.45–1.11)
≥17  13 0.58 (0.29–1.16) 0.61 (0.29–1.27) 0.63 (0.30–1.35)
p-value for trend 0.022 0.078 0.128
CVD
(n  = 41)
<10 9 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17  27 1.19 (0.54–2.60) 1.51 (0.67–3.41) 1.57 (0.69–3.59)
≥17  5 1.37 (0.44–4.27) 1.58 (0.47–5.21) 1.57 (0.46–5.32)
p-value for trend 0.568 0.356 0.348
Cancer
(n  = 77)
<10 29 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17  42 0.54 (0.32–0.91) 0.59 (0.34–1.01) 0.63 (0.37–1.10)
≥17 6  0.48 (0.19–1.22) 0.49 (0.19–1.29) 0.52 (0.19–1.40)
p-value for trend 0.025 0.050 0.088
Other  cause
(n = 24)
<10 11 1.00 (ref) 1.00 (ref) 1.00 (ref)
10–17  11 0.39 (0.17–0.92) 0.45 (0.19–1.11) 0.48 (0.19–1.20)
≥17  2 0.44 (0.10–2.06) 0.47 (0.10–2.34) 0.50 (0.10–2.57)
p-value for trend 0.064 0.126 0.164
Model 1: Adjusted for age.
Model 2: Additionally adjusted for education, marital status, alcohol intake, smoking, BMI, energy intake, total cholesterol/HDL ratio.
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bodel 3: Adjusted for all variables in model 2 and plasma ALT and GGT activities, a
alues in bold and italics are highlighting stadistical signiﬁcance of the results.
hat bilirubin is (1) strongly associated with the genotype, and (2)
esponsible for the protective effect of the UGT1A1*28 gene varia-
ion.
Our ﬁndings are further supported by clinical studies of can-
er morbidity. For example, in a large Chinese study on patients
ith colorectal cancer, the prevalence of Gilbert syndrome geno-
ype was very low, reaching only 1.4% [35]. Similarly low prevalence
f this Gilbert syndrome genotype (4.7%) was found in a study
f colon cancer by Liu et al. [36]. Serum bilirubin concentrations
ere reported to be negatively associated with non-dermatological
alignancies, and this effect was the most pronounced for colorec-
al cancer; subjects with Gilbert syndrome phenotype had 4-times
ower risk compared to individuals with normal bilirubin levels
18]. Similarly, in our previous study low serum bilirubin levels
ere associated with an increased risk of colorectal cancer in both
ales and females, whereas UGT1A1*28 allele carrier status was
roved to be protective against the development of colorectal can-
er in males [7].
The main limitation of our study is the relatively small num-
er of events, particularly deaths from speciﬁc causes. The averageP and urea concentration.
follow-up time of 6.4 years can also be considered short for the
development of chronic diseases and may be partly responsible
for some of the non-signiﬁcant ﬁndings. Further limitation is the
fact that site-speciﬁc cancer rates could not be assessed. Giving
the large variation within this disease group in terms of risk factor
proﬁle, future analyses should explore the link between bilirubin
and speciﬁc types of cancer. On the other hand, the prospective
design minimises the reverse causation bias, and the extensive set
of data on participants allows effective control for confounding.
In addition, the combination of observational and Mendelian ran-
domisation design, and the consistency of these two sets of ﬁndings,
supports the validity of our ﬁndings.
In conclusion, our study is consistent with earlier reports that
plasma bilirubin concentrations is negatively related to total mor-
tality; in our data, this association was  mostly driven by the effect
on a cancer, rather than CVD. These ﬁndings were further sup-
ported by the (non-signiﬁcant) pattern of associations between
mortality and the UGT1A1 promoter gene polymorphism which
was largely explained by plasma bilirubin. Larger epidemiological
studies, presumably on older populations, are needed to conﬁrm
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Table  5
Relationship between UGT1A1 promoter gene status and mortality with logistic regression models.
Cause of death UGT1A1 genotype Deaths
(n)
Model 1 Model 2
OR 95% CI OR 95% CI
All-causes
(n = 447)
6/6 191 1.00 (ref) 1.00 (ref)
6/7  198 0.91 (0.72–1.14) 0.97 (0.77–1.23)
7/7  58 0.83 (0.59–1.16) 0.98 (0.67–1.43)
p-value for trend 0.235 0.873
Sex interaction p-value 0.804 0.895
CVD
(n  = 139)
6/6 59 1.00 (ref) 1.00 (ref)
6/7  55 0.83 (0.56–1.21) 0.85 (0.58–1.25)
7/7  25 1.23 (0.75–2.01) 1.36 (0.78–2.39)
p-value for trend 0.739 0.631
Sex interaction p-value 0.477 0.545
Cancer
(n  = 211)
6/6 91 1.00 (ref) 1.00 (ref)
6/7  97 0.95 (0.70–1.29) 1.06 (0.77–1.44)
7/7  23 0.70 (0.43–1.14) 0.98 (0.58–1.68)
p-value for trend 0.208 0.889
Sex interaction p-value 0.734 0.693
Other  causes
(n = 97)
6/6 41 1.00 (ref) 1.00 (ref)
6/7  46 1.01 (0.65–1.56) 1.00 (0.64–1.55)
7/7  10 0.66 (0.33–1.34) 0.57 (0.26–1.25)
p-value for trend 0.374 0.293
Sex interaction p-value 0.581 0.571
Model 1: adjusted for age and sex.
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ur as well as previously published data on lacking relationship
etween bilirubin and CVD mortality, and to reveal the reasons for
his phenomenon.
bbreviations
VD cardiovascular diseases
GT1A1 bilirubin UDP-glucuronosyl transferase
APIEE Health, Alcohol, and Psychosocial factors in Eastern
Europe
CD International Classiﬁcation of Diseases
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